New CAR T Immune Cancer Therapy Approved

Immune-based cancer treatments are surging forward as the Food and Drug Administration (FDA) on Wednesday approved the second of a new technology called CAR T, this time to treat diffuse large b-cell lymphoma, a type of non-Hodgkin lymphoma. In August, the agency approved the first CAR T cell therapy, a type of gene therapy to treat acute lymphoblastic leukemia in children.